secwatch.observer — SEC 8-K summary
======================================

Issuer:     NAVIDEA BIOPHARMACEUTICALS, INC. (—)
CIK:        0000810509
Form:       8-K
Filed at:   2023-07-28T23:59:59+00:00
Accession:  0001437749-23-021059
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 5.02, 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Navidea appoints Craig Dais as CFO; stockholders approve reverse split and preferred conversion
--------------------------------------------------------------------------------

- Joseph Meyer resigns as Director, Finance and Accounting; last day August 11, 2023.
- Craig Dais appointed CFO effective July 28, 2023; base salary $200k, bonus target 20%, stock option target 150k/year.
- Stockholders approve reverse stock split (ratio 1:20 to 1:50) to maintain NYSE American listing; 47.9M for, 16.5M against.
- Stockholders approve issuance of >19.99% shares to Vice Chairman John K. Scott Jr. upon Series J conversion, resulting in change of control; 39.9M for, 15.9M against, 8.4M broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/0001437749-23-021059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/810509/000143774923021059/navb20230728_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-021059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer